The United Kingdom and the United States have hammered out a key bilateral deal that will preserve zero levies on British medicine exports entering the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase funding on medicines through the National Health Service (NHS). This commitment guarantees that duties on these vital goods will stay at nothing for a duration of 36 months.
This deal comes after previous threats to significantly raise duties on patented drug imports, with potential rates discussed as high as double the cost.
"This agreement with the Britain bolsters the global environment for new treatments and brings much-needed fairness to transatlantic drug exports," a statement noted.
Economic Significance
Pharmaceuticals are one of the UK's largest export categories to the US, which is by far the biggest market for leading British pharmaceutical firms.
Trade data indicate that in the 12 months leading up to September, the UK sold medicines totaling over eleven billion pounds to the US. This figure made up 17.4% of British export trade in that span.
"This deal safeguards work, increases funding and paves the way for the UK to establish itself as a global hub for life sciences," a minister commented.
Detailed UK Commitments
The deal includes several notable changes from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double total public funding on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage drug companies must pay back to the NHS to control costs will be capped at 15%. In the past, repayments were more than twenty percent.
Broader Context
The deal follows a protracted tension between the drug companies and the UK government over medicine costs and regulatory access.
This friction were intensified by arguments that American customers were paying several times more for the same drugs than patients in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar expansions have been announced toward US facilities.
One official stated that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a share of its total funding over the last ten years.
